-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amlitelimab in Atopic Dermatitis (Atopic Eczema)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Amlitelimab in Atopic Dermatitis (Atopic Eczema) Drug Details: Amlitelimab (KY-1005) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Amlitelimab in Hidradenitis Suppurativa
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Amlitelimab in Hidradenitis Suppurativa Drug Details: Amlitelimab (KY-1005) is under development for the treatment of...
-
Product Insights
NewHidradenitis Suppurativa – Drugs In Development, 2024
Empower your strategies with our Hidradenitis Suppurativa – Drugs In Development, 2024 report and make more profitable business decisions. Hidradenitis suppurativa (HS) is a chronic skin condition that features pea- to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop in areas where skin rubs together, such as the armpits, groin, between the buttocks, and under the breasts. The Hidradenitis Suppurativa drugs in development market research report provide comprehensive information on the therapeutics under development...
-
Product Insights
NewHemophilia A (Factor VIII Deficiency) – Drugs In Development, 2024
Empower your strategies with our Hemophilia A (Factor VIII Deficiency) – Drugs In Development, 2024 report and make more profitable business decisions. Hemophilia A is an X-linked recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury, or in the case of severe hemophilia, spontaneous hemorrhage. Symptoms may include bleeding...
-
Product Insights
NewMalaria – Drugs In Development, 2024
Empower your strategies with our Malaria – Drugs In Development, 2024 report and make more profitable business decisions. Malaria is a life-threatening blood disease caused by a parasite (Plasmodium) that is transmitted to humans by the Anopheles mosquito. People at increased risk of serious disease include young children and infants, travelers coming from areas with no malaria, and pregnant women and their unborn children. Symptoms may include fever, chills, headache, sweats, fatigue, enlarged spleen, nausea, and vomiting. Treatment includes anti-malarial medicines....
-
Product Insights
NewGraft Versus Host Disease (GVHD) – Drugs In Development, 2024
Empower your strategies with our Graft Versus Host Disease (GVHD) – Drugs In Development, 2024 report and make more profitable business decisions. Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps; nausea, vomiting, and diarrhea; dry or irritated eyes; jaundice; shortness of breath; vaginal dryness; and weight loss. Treatment includes immunosuppressants. The Graft Versus Host...
-
Product Insights
NewBone Marrow Transplant Rejection – Drugs In Development, 2024
Empower your strategies with our Bone Marrow Transplant Rejection – Drugs In Development, 2024 report and make more profitable business decisions. Bone marrow transplant rejection is a complication that can occur after a stem cell or bone marrow transplant. The newly transplanted donor cells attack the transplant recipient's body. Symptoms include chest pain, chills, drop in blood pressure, fever, flushing, funny taste in the mouth, headache, hives, nausea, pain, and shortness of breath. Treatment includes immunosuppressive drugs. The Bone Marrow Transplant...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Carenoprazan Hydrochloride in Duodenal Ulcer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Carenoprazan Hydrochloride in Duodenal Ulcer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Carenoprazan Hydrochloride in Duodenal Ulcer Drug Details: Carenoprazan hydrochloride is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Funobactam in Ventilator Associated Pneumonia (VAP)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Funobactam in Ventilator Associated Pneumonia (VAP) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Funobactam in Ventilator Associated Pneumonia (VAP)Drug Details:XNW-4107 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRNA-1365 in Respiratory Syncytial Virus (RSV) Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRNA-1365 in Respiratory Syncytial Virus (RSV) Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MRNA-1365 in Respiratory Syncytial Virus (RSV) InfectionsDrug Details:mRNA-1365 is under...